Ovid Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 6, 2018, discloses the results of the Annual Meeting of Stockholders held by Ovid Therapeutics Inc. on that date. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Both nominees were elected to serve three-year terms until the 2021 Annual Meeting.
- Barbara G. Duncan: 14,954,850 votes For; 1,689,047 votes Withheld; 2,205,777 Broker Non-Votes.
- Douglas Williams, PhD: 14,860,784 votes For; 1,783,163 votes Withheld; 2,205,777 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Votes: 18,838,956 For; 0 Against; 10,768 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Confirmation that Barbara G. Duncan and Douglas Williams, PhD, have been elected to the Board of Directors.
- Verification that KPMG LLP has been ratified as the independent auditor for the 2018 fiscal year.
- Review of the definitive proxy statement filed on April 24, 2018, for detailed background on the proposals.